Cantargia AB Sustainability Reports
Cantargia AB is a biotechnology company focused on developing targeted antibody-based treatments for cancer and inflammatory diseases. Its primary research revolves around the IL1RAP protein platform to enhance therapeutic efficacy and block pro-inflammatory signals.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300GKWRT7RXI4VS85
FIGI: BBG004T4DR07
14 reports from 2014 to 2025
